Coeptis Therapeutics Stock (NASDAQ: COEP)

Dernières nouvelles pour Coeptis Therapeutics (NASDAQ:COEP) Stock

Coeptis Therapeutics

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc. - Warrants

Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) reported quarterly losses of $(2.25) per share which missed the analyst consensus estimate of $(1.94) by 15.98 percent. This is a 50 percent decrease over losses of $(1.50) per share from the same period last year.

Earnings

Earnings Misses

News

ADVM

Adverum Biotechnologies Q1 EPS $(2.25) Misses $(1.94) Estimate

Datasea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTSS#NASDAQ">DTSS</a>) reported quarterly losses of $(0.24) per share. This is a 84.52 percent increase over losses of $(1.55) per share from the same period last year. The company reported $10.35 million in sales this quarter. This is a 648.66 percent increase over sales of $1.38 million the same period last year.

DTSS

Datasea Q3 EPS $(0.24) Up From $(1.55) YoY, Sales $10.35M Up From $1.38M YoY

General

SBCF

Seacoast Obtains Regulatory Approvals For The Acquisition Of Heartland Bancshares

North American Const Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) lowers FY2025 Adj EPS guidance from $2.65-$2.86 to $2.58-$2.79 vs $3.80 analyst estimate. Lowers FY2025 sales outlook from $1.00 billion-$1.14 billion to $975.27 million-$1.11 billion vs $1.29 billion estimate.

Guidance

North American Const Gr Lowers FY2025 Adj EPS Guidance from $2.65-$2.86 to $2.58-$2.79 vs $3.80 Est; Lowers FY2025 Sales Guidance from $1.00B-$1.14B to $975.27M-$1.11B vs $1.29B Est

FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) affirms FY2025 FFO guidance from $1.20-$1.26 to $1.20-$1.26 vs $1.16 analyst estimate..

FrontView REIT Affirms FY2025 FFO Guidance of $1.20-$1.26 vs $1.16 Est

Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is looking for FY2025 Adj EPS of $(1.80)-$(1.51) vs $(1.58) analyst estimate. sees sales of $85.000 million-$95.000 million vs $90.30 million analyst estimate.

SPIR

Spire Global Sees FY2025 Adj EPS $(1.80)-$(1.51) vs $(1.58) Est; Sees Sales $85.000M-$95.000M vs $90.30M Est

Galiano Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#TSX">GAU</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent. This is a 66.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $76.59 million which beat the analyst consensus estimate of $71.00 million by 7.87 percent. This is a 141.65 percent increase over sales of $31.70 million the same period last year.

Earnings Beats

TSX:GAU

Galiano Gold Q1 Adj. EPS $0.01 Misses $0.02 Estimate, Sales $76.59M Beat $71.00M Estimate

Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.04 by 75 percent. This is a 66.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $76.59 million which beat the analyst consensus estimate of $71.00 million by 7.87 percent. This is a 16.75 percent increase over sales of $65.60 million the same period last year.

Galiano Gold Q1 Adj. EPS $0.01 Misses $0.04 Estimate, Sales $76.59M Beat $71.00M Estimate

North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.77 by 53.25 percent. This is a 37.93 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $237.43 million which missed the analyst consensus estimate of $310.16 million by 23.45 percent. This is a 7.74 percent increase over sales of $220.37 million the same period last year.

North American Q1 Adj. EPS $0.36 Misses $0.77 Estimate, Sales $237.43M Miss $310.16M Estimate

Offerings

PNBK

Patriot National Bancorp Files For Mixed Shelf Offering Up To $250M

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 5 years by 26.92% on an annualized basis producing an average annual return of 41.93%. Currently, Fair Isaac has a market capitalization of $51.75 billion. 
Buying $1000 In FICO: If an investor had bought $1000 of FICO stock 5 years ago, it would be worth $5,797.86 today based on a price of $2125.90 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747258221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FICO

Here's How Much $1000 Invested In Fair Isaac 5 Years Ago Would Be Worth Today

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) lowers FY2025 Adj EPS guidance from $3.67-$3.76 to $3.57-$3.67 vs $5.23 analyst estimate. Lowers FY2025 sales outlook from $4.49 billion-$4.61 billion to $4.37 billion-$4.50 billion vs $6.50 billion estimate.

Stantec Lowers FY2025 Adj EPS Guidance from $3.67-$3.76 to $3.57-$3.67 vs $5.23 Est; Lowers FY2025 Sales Guidance from $4.49B-$4.61B to $4.37B-$4.50B vs $6.50B Est

Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.40) by 8.57 percent. This is a 67.92 percent increase over losses of $(3.99) per share from the same period last year. The company reported quarterly sales of $2.92 million which beat the analyst consensus estimate of $2.49 million by 17.35 percent. This is a 29.41 percent increase over sales of $2.25 million the same period last year.

KSCP

Knightscope Q1 EPS $(1.28) Beats $(1.40) Estimate, Sales $2.92M Beat $2.49M Estimate

California Water Service Group Files For Common Stock Offering Of Up To $350M

Natural Alternatives Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAII#NASDAQ">NAII</a>) reported quarterly losses of $(0.37) per share. This is a 37.04 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $28.77 million in sales this quarter. This is a 14.44 percent increase over sales of $25.14 million the same period last year.

NAII

Natural Alternatives Intl Q3 EPS $(0.37) Down From $(0.27) YoY, Sales $28.77M Up From $25.14M YoY

Stantec (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STN#TSX">STN</a>) affirms FY2025 Adj EPS guidance from $5.13-$5.26 to $5.13-$5.26 vs $5.24 analyst estimate. Affirms FY2025 sales outlook from $6.28 billion-$6.45 billion to $6.28 billion-$6.45 billion vs $6.53 billion estimate.

TSX:STN

Stantec Affirms FY2025 Adj EPS Guidance of $5.13-$5.26 vs $5.24 Est; Affirms FY2025 Sales Guidance of $6.28B-$6.45B vs $6.53B Est

Management

LAZR

Luminar Technologies Appoints Paul Ricci As CEO, Effective On Or About May 21, 2025

WIIM

GCTS

GCTS stock has given up its prior loss. GCT Semiconductor shares were trading lower after the company reported worse-than-expected Q1 financial results.

Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key figures from the quarter. 
The Details:  Luminar Technologies reported quarterly losses of $1.50 per share, which beat the analyst consensus estimate of losses of $1.78. Quarterly revenue came in at $18.89 million, which beat the Street estimate of $15.98 million.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue?utm_source=articleShare">Nvidia Climbs On Saudi AI Investments: Analyst Estimates $15 Billion To $20 Billion In Revenue&nbsp;</a>
Luminar announced a new operating plan enabled by a unified product architecture. The company expects it will reduce quarterly non-GAAP opreational expenditures by approximately half by the end of fiscal 2025 versus the beginning of fiscal 2024.
&#8220;In a world of macro uncertainty and adversity, we&#8217;re firing on all cylinders to ramp up production, ramp down costs and capitalize on the future, as evidenced by our announcements today,&#8221; said CEO Austin Russell.
&#8220;This kicks off our new operating plan for Luminar with a unified product platform, enabling radical focus and streamlining of the business, as well as unlocking value throughout our organization.&#8221;
LAZR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Luminar Technologies stock was down 1.68% at $4.68 after-hours on Wednesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Image: Shutterstock

Movers

Tech

Luminar Technologies Shares Slip After Q1 Results, New Operating Plan

Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) lowers FY2025 sales outlook from $29.00 million-$32.00 million to $26.00 million-$30.00 million vs $33.43 million estimate.

BNGO

Bionano Genomics Lowers FY2025 Sales Guidance from $29.00M-$32.00M to $26.00M-$30.00M vs $33.43M Est

Press Releases

NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

COEPTIS (COEP) Expands Global Footprint with Strategic India Tech Hub

Biotech

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders

NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market

BURU

CKPT

COEP

COIN

HOOD

KRON

MARA

OPTN

PPBI

PYPL

RGLS

RIOT

SWTX

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

Allakos

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

BioAtla

bluebird bio

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Kezar Life Sciences

OS Therapies

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Comments

Coeptis Therapeutics

Actualités

Dernières nouvelles pour Coeptis Therapeutics (NASDAQ:COEP) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL